File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Scopus: eid_2-s2.0-0345874657
- PMID: 17986555
- WOS: WOS:000188533200008
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Preventing peritoneal fibrosis - Insights from the laboratory
Title | Preventing peritoneal fibrosis - Insights from the laboratory |
---|---|
Authors | |
Keywords | Extracellular matrix Fibrosis TGFβ1 Vasculopathy |
Issue Date | 2003 |
Publisher | Multimed, Inc. The Journal's web site is located at http://pdiconnect.com |
Citation | Peritoneal Dialysis International, 2003, v. 23 SUPPL. 2, p. S37-S41 How to Cite? |
Abstract | ◆ Objective: Peritoneal fibrosis is one of the most serious complications of peritoneal dialysis (PD). Peritoneal fibrosis is characterized by activation of the peritoneal resident cells, accumulation and deposition of excess matrix proteins within the interstitium, and neoangiogenesis and vasculopathy of the peritoneal microvasculature. Compelling evidence now exists to show that elevated glucose concentrations present as the osmotic agent in PD solutions are, per se, responsible for those detrimental changes. Until alternative osmotic agents can fully replace glucose in PD solutions, novel therapeutic strategies are essential to preserve the structural and functional properties of the peritoneum. This review highlights recent experimental data that may offer potential strategies for preservation of the peritoneal structure and improvement of clinical outcome. ◆ Method: Literature review. ◆ Results: Compelling evidence now exists to show that the bioincompatible nature of PD solutions - in particular, elevated glucose concentrations and glucose byproducts - play a pivotal role in the initiation of peritoneal fibrosis. Animal and in vitro studies provide some insight into methods that can potentially be employed to alleviate or retard peritoneal fibrosis. Those methods include use of alterative osmotic agents (polyglucose or amino acids), administration of TGFβ1 antagonists, gene therapy, and pharmacologic interventions. ◆ Conclusions: Knowledge of the pathogenesis of peritoneal fibrosis has allowed independent researchers to design therapeutic strategies that abrogate excess matrix synthesis and deposition in cultured peritoneal cells and in animal models of experimental peritoneal fibrosis alike. Encouraging results have been obtained in those studies, but it remains to be determined whether the studied strategies can alleviate clinical disease. Future studies will enable us to establish specific molecules that can be targeted clinically to restrict the progressive deterioration of the peritoneal membrane as a biologic dialyzing organ. |
Persistent Identifier | http://hdl.handle.net/10722/162741 |
ISSN | 2023 Impact Factor: 2.7 2023 SCImago Journal Rankings: 0.933 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yung, S | en_US |
dc.contributor.author | Chan, TM | en_US |
dc.date.accessioned | 2012-09-05T05:22:59Z | - |
dc.date.available | 2012-09-05T05:22:59Z | - |
dc.date.issued | 2003 | en_US |
dc.identifier.citation | Peritoneal Dialysis International, 2003, v. 23 SUPPL. 2, p. S37-S41 | en_US |
dc.identifier.issn | 0896-8608 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/162741 | - |
dc.description.abstract | ◆ Objective: Peritoneal fibrosis is one of the most serious complications of peritoneal dialysis (PD). Peritoneal fibrosis is characterized by activation of the peritoneal resident cells, accumulation and deposition of excess matrix proteins within the interstitium, and neoangiogenesis and vasculopathy of the peritoneal microvasculature. Compelling evidence now exists to show that elevated glucose concentrations present as the osmotic agent in PD solutions are, per se, responsible for those detrimental changes. Until alternative osmotic agents can fully replace glucose in PD solutions, novel therapeutic strategies are essential to preserve the structural and functional properties of the peritoneum. This review highlights recent experimental data that may offer potential strategies for preservation of the peritoneal structure and improvement of clinical outcome. ◆ Method: Literature review. ◆ Results: Compelling evidence now exists to show that the bioincompatible nature of PD solutions - in particular, elevated glucose concentrations and glucose byproducts - play a pivotal role in the initiation of peritoneal fibrosis. Animal and in vitro studies provide some insight into methods that can potentially be employed to alleviate or retard peritoneal fibrosis. Those methods include use of alterative osmotic agents (polyglucose or amino acids), administration of TGFβ1 antagonists, gene therapy, and pharmacologic interventions. ◆ Conclusions: Knowledge of the pathogenesis of peritoneal fibrosis has allowed independent researchers to design therapeutic strategies that abrogate excess matrix synthesis and deposition in cultured peritoneal cells and in animal models of experimental peritoneal fibrosis alike. Encouraging results have been obtained in those studies, but it remains to be determined whether the studied strategies can alleviate clinical disease. Future studies will enable us to establish specific molecules that can be targeted clinically to restrict the progressive deterioration of the peritoneal membrane as a biologic dialyzing organ. | en_US |
dc.language | eng | en_US |
dc.publisher | Multimed, Inc. The Journal's web site is located at http://pdiconnect.com | en_US |
dc.relation.ispartof | Peritoneal Dialysis International | en_US |
dc.subject | Extracellular matrix | - |
dc.subject | Fibrosis | - |
dc.subject | TGFβ1 | - |
dc.subject | Vasculopathy | - |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Disease Models, Animal | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Peritoneal Fibrosis - Etiology - Prevention & Control | en_US |
dc.title | Preventing peritoneal fibrosis - Insights from the laboratory | en_US |
dc.type | Article | en_US |
dc.identifier.email | Yung, S:ssyyung@hku.hk | en_US |
dc.identifier.email | Chan, TM:dtmchan@hku.hk | en_US |
dc.identifier.authority | Yung, S=rp00455 | en_US |
dc.identifier.authority | Chan, TM=rp00394 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.pmid | 17986555 | - |
dc.identifier.scopus | eid_2-s2.0-0345874657 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0345874657&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 23 | en_US |
dc.identifier.issue | SUPPL. 2 | en_US |
dc.identifier.spage | S37 | en_US |
dc.identifier.epage | S41 | en_US |
dc.identifier.isi | WOS:000188533200008 | - |
dc.publisher.place | Canada | en_US |
dc.identifier.scopusauthorid | Yung, S=22636568800 | en_US |
dc.identifier.scopusauthorid | Chan, TM=7402687700 | en_US |
dc.identifier.issnl | 0896-8608 | - |